Form 4: Twist Bioscience CFO Sells Shares for Tax Obligations

Twist Bioscience's CFO, Adam Laponis, sold 5,517 shares of common stock to cover tax withholding obligations related to PSU vesting.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (TWST), sold 5,517 shares of common stock.
• The transaction occurred on October 30, 2025, at a price of $31.4443 per share.
• The sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations related to the vesting of Performance Stock Units (PSUs).
• This sale does not represent a discretionary trade by Mr. Laponis.
• Following the transaction, Mr. Laponis beneficially owns 111,008 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a mandatory 'sell to cover' for tax withholding, not a discretionary sale indicating a change in management's confidence in the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction related to tax obligations upon the vesting of equity awards, which is common across all industries for executives receiving performance-based compensation. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale is a routine, non-discretionary event for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's operational performance.

Key Dates

Recommendation

This transaction is a mandatory 'sell to cover' to satisfy tax obligations upon the vesting of Performance Stock Units, not a discretionary sale. As such, it does not reflect a change in the CFO's view of the company's fundamentals or future prospects. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

Twist Bioscience, TWST, Form 4, Insider Transaction, Stock Sale, CFO, Adam Laponis, Tax Withholding, PSU